Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02068586 · ClinicalTrials.gov registry record · Phase 2
Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma
A Phase 2 study of Iris Melanoma and Ciliary Body and Choroid Melanoma, Medium/Large Size, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Active
- Registry status
- Phase 2
- Development phase
- 210
- Enrollment target
- 1
- Study location
NCT02068586 is a Phase 2 study of Iris Melanoma and Ciliary Body and Choroid Melanoma, Medium/Large Size that is active but no longer recruiting, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 210 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02068586, a Phase 2 study of Iris Melanoma and Ciliary Body and Choroid Melanoma, Medium/Large Size, is active but no longer recruiting, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 210 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized phase II trial studies how well sunitinib malate or valproic acid works in preventing high-risk uveal (eye) melanoma from spreading to other parts of the body. Sunitinib malate may stop the transmission of growth signals into tumor cells and prevents these cells from growing. Valproic acid may change the expression of some genes in uveal melanoma and suppress tumor growth.
Conditions Studied
Interventions
- DRUG Sunitinib
- DRUG Valproic Acid
- DRUG Sunitinib Malate
- DRUG Sunitinib Malate + Valproic Acid
Study Locations (1)
Pennsylvania
- Sidney Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2014-11-19 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02068586
The ClinicalTrials.gov registry entry for NCT02068586 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Iris Melanoma appearing as the primary indexed condition, and to 4 interventions - of which Sunitinib is the first listed.
NCT02068586 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02068586 about?
NCT02068586 is a clinical study titled "Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma". This randomized phase II trial studies how well sunitinib malate or valproic acid works in preventing high-risk uveal (eye) melanoma from spreading to other parts of the body. Sunitinib malate may stop the transmission of growth signals into tumor cells and prevents these cells from growing. Valproi...
What is the current status of trial NCT02068586?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 210 participants. The study started on 2014-11-19. Estimated completion is 2026-12-31.
What conditions does trial NCT02068586 study?
This clinical trial studies the following conditions: Iris Melanoma, Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Stage I Intraocular Melanoma, Stage IIA Intraocular Melanoma.
What interventions are being tested in trial NCT02068586?
The interventions under investigation include: Sunitinib (DRUG), Valproic Acid (DRUG), Sunitinib Malate (DRUG), Sunitinib Malate + Valproic Acid (DRUG).
Who is sponsoring clinical trial NCT02068586?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02068586 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Iris Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Iris Melanoma
All registered trials for this condition
Ciliary Body and Choroid Melanoma, Medium/Large Size
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.